Zimmer Biomet’s (ZBH) “Hold (C-)” Rating Reiterated at Weiss Ratings

Weiss Ratings restated their hold (c-) rating on shares of Zimmer Biomet (NYSE:ZBH) in a research note issued to investors on Friday morning,Weiss Ratings reports.

A number of other equities analysts also recently commented on ZBH. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. BTIG Research raised their price target on shares of Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, October 13th. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Redburn Partners set a $130.00 price objective on Zimmer Biomet in a research report on Thursday, September 18th. Finally, Stifel Nicolaus raised their target price on Zimmer Biomet from $115.00 to $118.00 and gave the stock a “buy” rating in a research note on Friday, September 19th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $111.94.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $103.14 on Friday. The business’s 50 day moving average price is $101.86 and its 200 day moving average price is $97.64. The company has a market cap of $20.43 billion, a price-to-earnings ratio of 25.09, a PEG ratio of 2.37 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. Zimmer Biomet has a one year low of $89.22 and a one year high of $114.72.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. During the same period in the prior year, the business earned $2.01 EPS. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts predict that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s payout ratio is 23.36%.

Insider Activity

In other news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently made changes to their positions in the stock. Washington Trust Advisors Inc. purchased a new stake in shares of Zimmer Biomet in the 1st quarter valued at approximately $30,000. Columbia River Financial Group LLC purchased a new stake in shares of Zimmer Biomet in the 1st quarter valued at approximately $30,000. Accent Capital Management LLC purchased a new stake in Zimmer Biomet during the 1st quarter worth approximately $35,000. Cullen Frost Bankers Inc. increased its stake in Zimmer Biomet by 1,452.4% during the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 305 shares during the period. Finally, Cary Street Partners Investment Advisory LLC increased its stake in Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 149 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.